Dimethylamine

Dimethylamine

SCHEMBL3251310

CCc1c2n(c3c(C)ccc(Cl)c13)Cc1ccccc1-2.CNC

nearest known ligand 0.36

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MTNR1A P48039 12/20 0.36
▸ MTNR1B P49286 12/20 0.36
▸ MAPT P10636 4/20 0.34
▸ KDM4E B2RXH2 3/20 0.32
▸ HSD17B10 Q99714 3/20 0.32
▸ RAB9A P51151 3/20 0.32
▸ TSHR P16473 2/20 0.32
▸ NPC1 O15118 2/20 0.32
▸ SMN1; SMN2 Q16637 2/20 0.32
▸ TP53 P04637 1/20 0.32
▸ PKM P14618 1/20 0.32
▸ ALDH1A1 P00352 2/20 0.32
▸ HPGD P15428 2/20 0.32
▸ NPSR1 Q6W5P4 2/20 0.32
▸ CYP1A2 P05177 1/20 0.32
▸ CYP3A4 P08684 1/20 0.32
▸ CYP2D6 P10635 1/20 0.32
▸ CYP2C9 P11712 1/20 0.32
▸ NFKB1 P19838 1/20 0.32
▸ APEX1 P27695 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3251308 0.81 MTNR1A (0.35) MTNR1AMTNR1BMAPTKDM4EHSD17B10
Dimethylamine SCHEMBL3253647 0.81 MTNR1A (0.39) MTNR1AMTNR1BMAPTKDM4EHSD17B10
Dimethylamine SCHEMBL3248305 0.80 MTNR1A (0.39) MTNR1AMTNR1BMAPTKDM4EHSD17B10
Dimethylamine SCHEMBL3253217 0.78 MTNR1A (0.42) MTNR1AMTNR1BMAPTKDM4EHSD17B10
Dimethylamine SCHEMBL3254581 0.72 MTNR1A (0.46) MTNR1AMTNR1BMAPTKDM4EHSD17B10
Dimethylamine SCHEMBL3263635 0.71 MTNR1A (0.42) MTNR1AMTNR1BMAPTKDM4EHSD17B10
Dimethylamine SCHEMBL3253541 0.70 MTNR1A (0.61) MTNR1AMTNR1BMAPTKDM4EHSD17B10
Dimethylamine SCHEMBL3252770 0.70 MTNR1A (0.65) MTNR1AMTNR1BMAPTKDM4EHSD17B10
Dimethylamine SCHEMBL3256437 0.70 MTNR1A (0.39) MTNR1AMTNR1BMAPTKDM4EHSD17B10
Dimethylamine SCHEMBL3250889 0.70 MTNR1A (0.42) MTNR1AMTNR1BMAPTKDM4EHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1537113-B9 ARYLALKYL INDOLES HAVING SEROTONIN RECEPTOR AFFINITY USEFUL AS THERAPEUTIC AGENTS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM SUVEN LIFE SCIENCES LTD (IN) 2010-05-26 — — EP claimed
EP-1537113-B1 ARYLALKYL INDOLES HAVING SEROTONIN RECEPTOR AFFINITY USEFUL AS THERAPEUTIC AGENTS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM SUVEN LIFE SCIENCES LTD (IN) 2009-10-07 — — EP claimed
EP-1537113-A1 ARYLALKYL INDOLES HAVING SEROTONIN RECEPTOR AFFINITY USEFUL AS THERAPEUTIC AGENTS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM Suven Pharmaceuticals Ltd. (IN) 2005-06-08 — — EP claimed
WO-2004000845-A1 ARYLALKYL INDOLES HAVING SERTONIN RECEPTOR AFFINITY USEFUL AS THERAPEUTIC AGENTS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM SUVEN LIFE SCIENCES LIMITED (IN) 2003-12-31 — — WO claimed
EP-1537113-B9 ARYLALKYL INDOLES HAVING SEROTONIN RECEPTOR AFFINITY USEFUL AS THERAPEUTIC AGENTS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM SUVEN LIFE SCIENCES LTD (IN) 2010-05-26 — — EP disclosed
EP-1537113-B1 ARYLALKYL INDOLES HAVING SEROTONIN RECEPTOR AFFINITY USEFUL AS THERAPEUTIC AGENTS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM SUVEN LIFE SCIENCES LTD (IN) 2009-10-07 — — EP disclosed
US-7297711-B2 Arylalkyl indoles having serotonin receptor affinity useful as therapeutic agents, process for their preparation and pharmaceutical compositions containing them SUVEN LIFE SCIENCES LIMITED (IN) 2007-11-20 — — US disclosed
US-20050203103-A1 Arylalkyl indoles having serotonin receptor affinity useful as therapeutic agents, process for their preparation and pharmaceutical compositions containing them SUVEN LIFE SCIENCES LIMITED (IN) 2005-09-15 — — US disclosed
EP-1537113-A1 ARYLALKYL INDOLES HAVING SEROTONIN RECEPTOR AFFINITY USEFUL AS THERAPEUTIC AGENTS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM Suven Pharmaceuticals Ltd. (IN) 2005-06-08 — — EP disclosed
WO-2004000845-A1 ARYLALKYL INDOLES HAVING SERTONIN RECEPTOR AFFINITY USEFUL AS THERAPEUTIC AGENTS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM SUVEN LIFE SCIENCES LIMITED (IN) 2003-12-31 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050203103-A1 Arylalkyl indoles having serotonin receptor affinity useful as therapeutic agents, process for their preparation and pharmaceutical compositions containing them TPH1, HTR1A, HTR7 MTNR1A 76/4885MTNR1B 105/4885MAPT 240/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback